Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.
about
Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C.Role of Marine Natural Products in the Genesis of Antiviral AgentsHepatitis C virus infection in san francisco’s HIV-infected urban poorManaging Occupational Risks for Hepatitis C Transmission in the Health Care SettingTherapeutic issues in HIV/HCV-coinfected patientsHepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort StudyFactors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern ChinaUnderlying Pathophysiology of HCV Infection in HIV-Positive Drug UsersTreatment optimization for HIV/HCV co-infected patients.Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugsPatient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV.Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of ChinaFactors that influence an HIV coinfected patient's decision to start hepatitis C treatmentIL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapyThe potential role of biomarkers in HIV preventive vaccine trialsCoping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast.Transplantation in the HIV+ patient.HCV chronic hepatitis in patients with HIV: clinical management issues.Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patientsOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionDifferential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cellsThe effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.Characteristics of HCV co-infection among HIV infected individuals from an area with high risk of blood-borne infections in central China.Risk Factors and Seroprevalence of Hepatitis C among Patients Hospitalized at Mulago Hospital, Uganda.Factors associated with seronegative chronic hepatitis C virus infection in HIV infectionAssessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.Hepatitis C and HIV-1 coinfection.The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UKImpact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problemsInteractions between viruses in transplant recipients.Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.
P2860
Q24804388-AF506BB9-B6F1-4BCD-B989-6C19BF23D1E9Q24815408-58FA2B38-D787-4C67-8724-066FB0118C45Q26796360-09B5A16B-7EEA-48DB-9B84-943819DFB7BDQ27473306-808A7A2F-679B-4415-AD2B-A3F63CB0C9CCQ27477626-1769CADC-95F4-4FEF-B172-F52D5D51210EQ27481053-D11A19CF-86AB-4D5E-9C6A-71F3274015C5Q27485912-7C169953-355A-48AE-AF31-E291C29865E6Q27488825-4A945EC5-22EB-4EFF-B822-EA771018E4B0Q27489073-A853F4FF-F282-4D6D-8301-C9BA98A26FF0Q30235034-5AEAF252-9252-4F12-822E-7C8537370A05Q30369227-CE48792D-3175-4078-BDD4-2798872375E2Q30405780-F83ACBAF-8B60-4111-BD6F-D9A28DE26D1AQ33575488-261E781C-0A04-45EA-9FE4-6D60F4B7BBE9Q33597796-6EC38685-BD76-4C3A-8616-96671278154CQ33705645-7D83B352-C241-477E-BF24-E5B70C78D18DQ34049322-F087F9E6-E221-48B6-B3F6-2F7A959E12F5Q34059957-183E66A2-16DC-40B8-96A5-970A1A67600DQ34087766-502B9F55-81E1-4560-B64B-BF1F15960C03Q34719074-9FBBE704-6439-42FC-91C4-5C4549CF6188Q34756205-67AC2619-BDB7-4434-8C8A-3A7DCF2EFA6AQ34788754-0C9D22B0-CABB-4477-858A-3267369E9A45Q34976284-AAE0CE59-4447-4546-80ED-3B6DE717F071Q35033949-0A9B607A-BEF6-488A-95E3-2A1C748B2D01Q35077992-95D6B61A-1C4A-472D-99D8-8C4774ACB562Q35102095-1120D596-5F0C-4ACA-8374-800EB9EE9E82Q35141727-F35A38E4-5B45-47F3-87DC-CB135E43C705Q35157605-5D35DFC4-5763-4C3A-808C-A6C106CEB113Q35206642-FE8B0DAE-3522-41D6-8AE1-C4EFDB2DCD6BQ35397221-165EA83C-870C-456F-8773-D03227C08340Q35566908-C4750768-E098-4551-A94C-84E277B911E9Q35595027-9273E92C-13A7-4BD5-9890-363167186AF3Q35725969-0DB539E1-1E74-4E15-A53F-532B2574FD56Q35905025-3EB6BDD3-DDE1-4212-ABBB-CAB24EFFC4BDQ35906594-265F9EBC-FCFC-40BB-86D6-7807C1C44575Q36008565-24D89765-2E44-4060-9DAE-96A2A5B4185BQ36016477-5C2A328F-CD92-477E-AFC5-C2005168F201Q36019409-B5B73120-FE2B-4B5E-B329-9A4D52845A65Q36078430-6434CFCB-EB67-495D-8425-AE90DCE6374CQ36083457-12D733D4-215A-4B21-956E-D7408A2C9B6BQ36272393-A2F9F40F-2001-4231-8950-1AFC84A39B1F
P2860
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Hepatitis C virus infection as ...... human immunodeficiency virus.
@ast
Hepatitis C virus infection as ...... human immunodeficiency virus.
@en
type
label
Hepatitis C virus infection as ...... human immunodeficiency virus.
@ast
Hepatitis C virus infection as ...... human immunodeficiency virus.
@en
prefLabel
Hepatitis C virus infection as ...... human immunodeficiency virus.
@ast
Hepatitis C virus infection as ...... human immunodeficiency virus.
@en
P2093
P356
P1476
Hepatitis C virus infection as ...... human immunodeficiency virus.
@en
P2093
P304
P356
10.1086/313842
P407
P478
30 Suppl 1
P577
2000-04-01T00:00:00Z